Alliance for Cancer Gene Therapy (ACGT), the nation's only public charity exclusively funding cancer cell and gene therapy research, announced today that Kevin Honeycutt will be joining ACGT as its new CEO and President, effective December 3, 2018. Mr. Honeycutt was most recently the President and CEO of the Avon Breast Cancer Crusade (ABCC) since 2015. At ACGT, his principal role will be to enhance the vision of ACGT, begun in 2001 by its co-founders, Barbara Netter and her late husband Edward, to spearhead ACGT’s current focus on funding the next generation of challenges brought by metastatic cancers and solid tumors, and to continue to build our alliances and joint ventures.
Mrs. Netter stated that, “We are delighted to have Kevin as ACGT’s new CEO and President at this momentous time in the field of cancer cell and gene therapy. His experience at ABCC, in which he led several highly successful fundraising campaigns, positions him to hit the ground running to oversee ACGT‘s fundraising and grants program. Kevin brings a depth of knowledge and experience in the oncology space and strategic thinking which perfectly fits within the ACGT model.”
Mr. Honeycutt said that, “ACGT’s outstanding Board of Directors and pre-eminent Scientific Advisory Council, together with the leadership of Barbara Netter, the ACGT staff, and ACGT’s current and past grant recipients, were key to my enthusiasm in joining ACGT. Given the remarkable advances being made in the field of cancer cell and gene therapy, it is an opportune time to be working in cancer research with significant opportunities to advance the understanding of how to treat the disease and give patients the best chances for successful long-term favorable outcomes.”
Prior to his years at ABCC, Mr. Honeycutt served as Executive Director of the Avon Foundation for Women for five years, and in cause marketing. He previously led projects for, among others, the American Diabetes Association, DaVita, Inc. / The Kidney Trust, the Entertainment Industry Foundation and the Jane Goodall Institute.
About Alliance for Cancer Gene Therapy (ACGT)
Established in 2001, ACGT is the nation’s only nonprofit dedicated exclusively to funding cell and gene therapy research for all types of cancer. One hundred percent of contributions go directly to research. Since its inception, ACGT has funded some of the underlying science that has resulted in the formation of either licensing agreements or biotech companies including Novartis, Ziopharm, Juno, Tmunity and Turnstone Biologics, all of which are in various stages of bringing new treatments to patients. ACGT has funded 58 grants in the U.S. and Canada to conduct and accelerate critically needed innovative research. 36 of those grants have gone to Young Investigators for basic research and 22 grants to Clinical Investigators, totaling more than $29 million in funding. ACGT is located at 96 Cummings Point Road, Stamford, Connecticut 06902; 203-358-5055. To learn more, visit acgtfoundation.org or join the ACGT community on Facebook, Twitter and YouTube at @acgtfoundation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005255/en/
Alliance for Cancer Gene Therapy
Jenifer Howard, 203-273-4246
jhoward@jhowardpr.com